%0 Journal Article %A Qi Tan %A Rui Min %A Hong Wang %A Wei-Ping Xie %A Zhi-Hui Xu %A Mao Huang %A Wei-Guo Xu %T Immunotherapy using IL-2 potentially reverse disorders of Th1 /Th17 response in patients with MDR-TB %D 2013 %J European Respiratory Journal %P P2816 %V 42 %N Suppl 57 %X Objective: Prevalence of multidrug-resistant tuberculousis(MDR-TB) worldwide today is urgent. Dysregulation of Th1/Th17 was associated with the pathogenesis and the clinical outcome of MDR-TB infection. Adjunctive immunotherapy with IL-2 evidently enhanced the immune response in mouse model of TB infection .This clinical study investigated the therapeutic effects of Recombinant Human Interleukin-2(rhIL-2) co-administrated with optimized antituberculosis chemotherapy.Methods:We examined Th17 cells and Th1 cells by flow cytometry in peripheral blood of 18 healthy subjects(HCs),16 drug-sensitive TB patients(DS-TBs)and 26 MDR-TB patients(13 using optimized antituberculosis chemotherapy,13 using rhIL-2 plus optimized antituberculosis chemotherapy).Results:We found downregulated Th1 and upregulated Th17 expression in MDR-TBs before treatment. After 7-month treatment, patients using rhIL-2 plus chemotherapy showed more remarkble higher Th1 cell expression than that in patients with chemotherapy .All the MDR-TBs after 7-month treatment showed downregulated Th17 cell expression ,the downregulation in patients after rhIL-2 plus chemotherapy was more significant and normalized to that in HCs.Conclusions:These data provided evidence that immunotherapy with rhIL-2 reverse the disorders of Th1 /Th17 activation in MDR-TB infection,which may promote an enhanced antimicrobial response to improve outcomes in MDR-TB patients. %U https://erj.ersjournals.com/content/erj/42/Suppl_57/P2816.full.pdf